Tvardi Therapeutics (TVRD) News Today $5.00 -0.16 (-3.10%) As of 03:39 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVRD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Faruqi & Faruqi Reminds Tvardi Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 3, 2025 - TVRDOctober 23 at 1:05 PM | prnewswire.comFY2025 EPS Estimates for TVRD Boosted by Cantor FitzgeraldOctober 18, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Downgraded to Sell Rating by Wall Street ZenOctober 18, 2025 | marketbeat.comCantor Fitzgerald Brokers Lift Earnings Estimates for TVRDOctober 16, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Research Coverage Started at BarclaysOctober 16, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Raymond James FinancialOctober 16, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Earns "Sell (E+)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comTVRD SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsOctober 15, 2025 | prnewswire.comBTIG Research Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock PriceOctober 15, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Piper SandlerOctober 15, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Cantor FitzgeraldOctober 15, 2025 | americanbankingnews.comTvardi Therapeutics (NASDAQ:TVRD) Trading Down 83.9% Following Analyst DowngradeOctober 15, 2025 | americanbankingnews.comWeiss Ratings Reaffirms "Sell (E+)" Rating for Tvardi Therapeutics (NASDAQ:TVRD)October 14, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Downgraded to "Market Perform" Rating by Raymond James FinancialOctober 14, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Stock Rating Upgraded by BarclaysOctober 14, 2025 | marketbeat.comWhy Tvardi Therapeutics (TVRD) Is Down 83.3% After Disappointing Phase 2 TTI-101 IPF Trial ResultsOctober 14, 2025 | finance.yahoo.comTvardi Therapeutics (NASDAQ:TVRD) Shares Down 83.9% After Analyst DowngradeOctober 13, 2025 | marketbeat.comTvardi Therapeutics: 'Sell' Rating On IPF Drug TTI-101 Advancement UncertaintyOctober 13, 2025 | seekingalpha.comTVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi TherapeuticsOctober 13, 2025 | businesswire.comTvardi Therapeutics Stock Plunges 30% After Disappointing IPF Trial ResultsOctober 13, 2025 | msn.comTvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock SinksOctober 13, 2025 | benzinga.comTvardi Therapeutics (NASDAQ:TVRD) Price Target Cut to $15.00 by Analysts at BTIG ResearchOctober 13, 2025 | marketbeat.comCantor Fitzgerald Downgrades Tvardi Therapeutics (NASDAQ:TVRD) to NeutralOctober 13, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Cut to Neutral at Piper SandlerOctober 13, 2025 | marketbeat.comTvardi Therapeutics stock plunges after failed IPF trial dataOctober 13, 2025 | investing.comWhy Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?October 13, 2025 | msn.comTvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary FibrosisOctober 13, 2025 | businesswire.comTvardi Therapeutics, Inc. (NASDAQ:TVRD) most popular amongst retail investors who own 57% of the shares, institutions hold 26%October 11, 2025 | uk.finance.yahoo.comTvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of "Buy" by BrokeragesOctober 3, 2025 | marketbeat.comBTIG biotech analyst holds a dinner meetingSeptember 25, 2025 | msn.comTvardi Therapeutics (TVRD) Receives a Buy from Piper SandlerSeptember 22, 2025 | theglobeandmail.comTvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 0.2% - Here's What HappenedSeptember 17, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth PlansAugust 31, 2025 | finance.yahoo.comTvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's WhyAugust 24, 2025 | marketbeat.comTvardi Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 21, 2025 | theglobeandmail.comTvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPSAugust 16, 2025 | marketbeat.comTvardi Therapeutics expects cash to fund operations into Q4 2026August 15, 2025 | msn.comTvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last yearAugust 15, 2025 | msn.comTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comTvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James FinancialJuly 14, 2025 | marketbeat.comEquities Analysts Offer Predictions for TVRD FY2025 EarningsJuly 14, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics (NASDAQ:TVRD) Earns Overweight Rating from Analysts at Cantor FitzgeraldJuly 11, 2025 | marketbeat.comTvardi Therapeutics (NASDAQ:TVRD) Stock Price Up 2.4% - What's Next?July 11, 2025 | marketbeat.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.com Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TVRD Media Mentions By Week TVRD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TVRD News Sentiment▼0.460.63▲Average Medical News Sentiment TVRD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TVRD Articles This Week▼33▲TVRD Articles Average Week Get the Latest News and Ratings for TVRD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Tvardi Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Edgewise Therapeutics News Janux Therapeutics News Harmony Biosciences News Aurinia Pharmaceuticals News Schrodinger News Phibro Animal Health News Harrow News Nanobiotix News Evotec News Syndax Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TVRD) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredFree: The Crypto Summit That Could Change Your LifeFed cuts unleash crypto's next wave The smart money is already moving. This is your chance to see their car...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
